Biodesix Inc Ordinary Shares BDSX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BDSX is a good fit for your portfolio.
News
-
Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024
-
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
-
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
-
Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center
-
Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights
-
Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference
-
Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024
Trading Information
- Previous Close Price
- $1.31
- Day Range
- $1.31–1.33
- 52-Week Range
- $1.04–2.20
- Bid/Ask
- $1.31 / $1.32
- Market Cap
- $150.24 Mil
- Volume/Avg
- 11,197 / 137,628
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.19
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 217
- Website
- https://www.biodesix.com
Comparables
Valuation
|
Metric
|
BDSX
|
VCYT
|
ACRS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 26.68 | — |
Price/Book Value | 27.53 | 1.41 | 0.59 |
Price/Sales | 2.19 | 4.05 | 2.93 |
Price/Cash Flow | — | 30.22 | — |
Price/Earnings
BDSX
VCYT
ACRS
Financial Strength
|
Metric
|
BDSX
|
VCYT
|
ACRS
|
|---|---|---|---|
Quick Ratio | 1.02 | 4.19 | 3.86 |
Current Ratio | 1.19 | 4.66 | 4.16 |
Interest Coverage | −4.47 | −5,596.07 | — |
Quick Ratio
BDSX
VCYT
ACRS
Profitability
|
Metric
|
BDSX
|
VCYT
|
ACRS
|
|---|---|---|---|
Return on Assets (Normalized) | −51.98% | 7.85% | −38.26% |
Return on Equity (Normalized) | −1,067.17% | 8.41% | −50.08% |
Return on Invested Capital (Normalized) | −72.26% | 7.64% | −49.93% |
Return on Assets
BDSX
VCYT
ACRS
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Zljzvkfjw | Zwxnh | $218.1 Bil | |
DHR
| Danaher Corp | Cdxvznptw | Hpnsyvg | $182.9 Bil | |
IQV
| IQVIA Holdings Inc | Xtxzfzwl | Lhcpxg | $42.4 Bil | |
A
| Agilent Technologies Inc | Wwkrzvzd | Nynx | $40.3 Bil | |
IDXX
| IDEXX Laboratories Inc | Cqgfdhzxms | Ykhtgf | $39.3 Bil | |
MTD
| Mettler-Toledo International Inc | Pszftlymv | Mztlcrt | $26.7 Bil | |
ICLR
| Icon PLC | Vfssvby | Kfbnj | $24.9 Bil | |
ILMN
| Illumina Inc | Gdwvnrm | Mccktc | $19.7 Bil | |
WAT
| Waters Corp | Qsszbrbzjt | Lpqc | $18.7 Bil | |
LH
| Laboratory Corp of America Holdings | Qrxhktcqn | Vrtjfc | $17.0 Bil |